Home›Clinical trials›Illinois

GLP-1 clinical trials in Illinois: 29 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

29 GLP-1 clinical trials are recruiting at 41 sites in 11 cities across Illinois. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Illinois

  1. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

    Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

    4 sites in Illinois

    • Great Lakes Clinical Trials - Ravenswood, Chicago. 7732753500
    • Greater Chicago Specialty Physicians, Schaumburg. 8475992492
    • Arnold Arthritis & Rheumatology, Skokie
    • Willow Rheumatology and Wellness PLLC, Willowbrook. 4349628466

    NCT06864026 on ClinicalTrials.gov. See whether you qualify.

  2. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Brigham and Women's Hospital plans to enroll 6,000 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    2 sites in Illinois

    NCT05390892 on ClinicalTrials.gov. See whether you qualify.

  3. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Novo Nordisk A/S plans to enroll 2,500 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    5 sites in Illinois
    • Cedar-Crosse Research Center, Chicago
    • Macoupin Fam Practice Ctr, LLP, Gillespie
    • Clinical Investigation Spec Gurnee, Gurnee
    • Endeavor Health, Skokie
    • Evanston Premier Hlthcr Res, Skokie

    NCT07564414 on ClinicalTrials.gov. See whether you qualify.

  1. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Eli Lilly and Company plans to enroll 125 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    2 sites in Illinois

    • Ann and Robert Lurie Children's Hospital of Chicago, Chicago. 312-503-1499
    • University of Illinois at Chicago, Chicago

    NCT06672549 on ClinicalTrials.gov. See whether you qualify.

  2. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Kailera plans to enroll 1,200 participants.

    A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    2 sites in Illinois

    • Kailera Clinical Site, Chicago
    • Kailera Clinical Site, Skokie

    NCT07284979 on ClinicalTrials.gov. See whether you qualify.

  3. A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

    Phase 3. Eli Lilly and Company plans to enroll 300 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people lose weight.

    Who can join. Children and teens 12 to 17, have obesity.

    1 site in Illinois

    • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

    NCT06439277 on ClinicalTrials.gov. See whether you qualify.

  4. Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

    Phase 3. University of Chicago plans to enroll 200 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with atrial fibrillation lose weight.

    Who can join. Adults 18 to 75, have obesity or are overweight, BMI 30+.

    1 site in Illinois

    NCT06499857 on ClinicalTrials.gov. See whether you qualify.

  5. A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

    Phase 3. Eli Lilly and Company plans to enroll 150 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 12 to 17, have obesity.

    1 site in Illinois

    • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

    NCT06672939 on ClinicalTrials.gov. See whether you qualify.

  6. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Eli Lilly and Company plans to enroll 350 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    1 site in Illinois

    • Rush University Medical Center, Chicago

    NCT06937086 on ClinicalTrials.gov. See whether you qualify.

  7. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Eli Lilly and Company plans to enroll 290 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    1 site in Illinois

    • Rush University Medical Center, Chicago

    NCT06937099 on ClinicalTrials.gov. See whether you qualify.

The other 19 studies recruiting in Illinois

  1. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Eli Lilly and Company plans to enroll 800 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    1 site in Illinois

    NCT07153471 on ClinicalTrials.gov. See whether you qualify.

  2. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Eli Lilly and Company plans to enroll 4,500 participants.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    1 site in Illinois

    • University of Chicago Medical Center, Chicago

    NCT07165028 on ClinicalTrials.gov. See whether you qualify.

  3. Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    Phase 3. VA Office of Research and Development plans to enroll 622 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18 to 80, have alcohol use disorder, BMI 21+.

    1 site in Illinois

    • Edward Hines Jr. VA Hospital, Hines, IL, Hines. 708-202-8387

    NCT07218354 on ClinicalTrials.gov. See whether you qualify.

  4. A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

    Phase 3. Amgen plans to enroll 300 participants.

    A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

    1 site in Illinois

    • Endeavor Health, Skokie

    NCT07575399 on ClinicalTrials.gov. See whether you qualify.

  5. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. AstraZeneca plans to enroll 1,200 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Illinois

    • Research Site, Melrose Park

    NCT07662213 on ClinicalTrials.gov. See whether you qualify.

  6. A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

    Phase 3. Novo Nordisk A/S plans to enroll 285 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Adults 18+, are overweight, BMI 27+.

    1 site in Illinois

    • Walgreens - Store 11760, Oak Park

    NCT07745504 on ClinicalTrials.gov. See whether you qualify.

  7. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Boehringer Ingelheim plans to enroll 600 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Illinois

    • Evanston Premier Healthcare Research LLC, Skokie. 833-602-2368

    NCT07754461 on ClinicalTrials.gov. See whether you qualify.

  8. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Eli Lilly and Company plans to enroll 1,481 participants.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    2 sites in Illinois

    • Great Lakes Clinical Trials - Ravenswood, Chicago
    • NorthShore University Health System, Skokie

    NCT06143956 on ClinicalTrials.gov. See whether you qualify.

  9. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Novo Nordisk A/S plans to enroll 230 participants.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    2 sites in Illinois

    • Cedar-Crosse Research Center, Chicago
    • Great Lakes Clinical Trials, Chicago

    NCT07639021 on ClinicalTrials.gov. See whether you qualify.

  10. Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

    Phase 2. T. John Winhusen, PhD plans to enroll 310 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with opioid use disorder cut down on opioids.

    Who can join. Adults 18+, have opioid use disorder, BMI 23+.

    1 site in Illinois

    NCT06651177 on ClinicalTrials.gov. See whether you qualify.

  11. A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living

    Phase 2. Novo Nordisk A/S plans to enroll 465 participants.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0519-0130, can help people with chronic kidney disease protect their kidneys.

    Who can join. Adults 18+, have chronic kidney disease, BMI 27+.

    1 site in Illinois

    • Endeavor Health, Skokie

    NCT06717698 on ClinicalTrials.gov. See whether you qualify.

  12. Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation

    Phase 2. AgelessRx plans to enroll 150 participants.

    A study testing whether a long-used diabetes pill, metformin, affects healthy aging.

    Who can join. Adults 40 to 85, are joining a healthy-aging study, BMI 22+.

    1 site in Illinois

    NCT07092618 on ClinicalTrials.gov. See whether you qualify.

  13. A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Novo Nordisk A/S plans to enroll 270 participants.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    1 site in Illinois

    • Cedar-Crosse Research Center, Chicago

    NCT07415954 on ClinicalTrials.gov. See whether you qualify.

  14. Multi-Site Trial of Tirzepatide for Smoking Cessation

    Phase 2. University of Southern California plans to enroll 300 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people quit smoking.

    Who can join. Adults 21 to 65, are trying to quit smoking, BMI 25+.

    1 site in Illinois

    • University of Chicago Pritzker School of Medicine, Chicago. 773-834-2244

    NCT07602699 on ClinicalTrials.gov. See whether you qualify.

  15. Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss

    Phase 1. Nicholas Skertich plans to enroll 42 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people lose weight.

    Who can join. Adults 18 to 65, have obesity, BMI 35+.

    1 site in Illinois

    NCT06734273 on ClinicalTrials.gov. See whether you qualify.

  16. Preoperative Weight Loss for Open Abdominal Wall Reconstruction

    Benjamin T. Miller plans to enroll 258 participants.

    A study of a GLP-1 medicine, semaglutide, in people with abdominal wall hernia.

    Who can join. Adults 18+, have abdominal wall hernia, BMI 40+.

    1 site in Illinois

    NCT05925959 on ClinicalTrials.gov. See whether you qualify.

  17. Postprandial Response to Fruit Juice

    Ocean Spray Cranberries, Inc plans to enroll 18 participants.

    A study listed on ClinicalTrials.gov.

    Who can join. Adults 18 to 45, BMI 18.5+.

    1 site in Illinois

    NCT07103083 on ClinicalTrials.gov. See whether you qualify.

  18. People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

    Northwestern University plans to enroll 100 participants.

    A study in people with multiple sclerosis.

    Who can join. Adults 18 to 70, have multiple sclerosis, BMI 24+.

    1 site in Illinois

    NCT07207148 on ClinicalTrials.gov. See whether you qualify.

  19. Effects of Dihydroberberine (DHB) on GLP-1, Glycemic Control, Appetite, and Mood in Adults With Pre-Diabetes

    Nanjing Nutrabuilding Bio-tech Co., Ltd plans to enroll 54 participants.

    A study in people with prediabetes.

    Who can join. Adults 35 to 65, have prediabetes, BMI 25+.

    1 site in Illinois

    NCT07210684 on ClinicalTrials.gov. See whether you qualify.

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
Written and edited by John SamarasAbout this siteContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.